ValuEngine downgraded shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) from a hold rating to a sell rating in a research note issued to investors on Thursday.

AVXL has been the subject of a number of other reports. Zacks Investment Research downgraded shares of Anavex Life Sciences Corp. from a buy rating to a hold rating in a research note on Wednesday, June 7th. Maxim Group set a $15.00 price objective on shares of Anavex Life Sciences Corp. and gave the stock a buy rating in a report on Monday, August 7th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $11.13.

Anavex Life Sciences Corp. (AVXL) opened at 4.14 on Thursday. The firm’s market capitalization is $174.59 million. Anavex Life Sciences Corp. has a 1-year low of $2.76 and a 1-year high of $6.30. The company’s 50-day moving average price is $4.52 and its 200-day moving average price is $4.52.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.09) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.09). Equities research analysts expect that Anavex Life Sciences Corp. will post ($0.38) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Anavex Life Sciences Corp. (AVXL) Rating Lowered to Sell at ValuEngine” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/02/anavex-life-sciences-corp-avxl-rating-lowered-to-sell-at-valuengine.html.

Institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. purchased a new position in Anavex Life Sciences Corp. during the first quarter valued at $105,000. Northwest Investment Counselors LLC bought a new stake in shares of Anavex Life Sciences Corp. during the 2nd quarter valued at $106,000. American International Group Inc. boosted its holdings in shares of Anavex Life Sciences Corp. by 7.1% during the 1st quarter. American International Group Inc. now owns 20,103 shares of the biotechnology company’s stock valued at $115,000 after buying an additional 1,329 shares in the last quarter. State of Wisconsin Investment Board bought a new stake in shares of Anavex Life Sciences Corp. during the 2nd quarter valued at $151,000. Finally, Alliancebernstein L.P. bought a new stake in shares of Anavex Life Sciences Corp. during the 2nd quarter valued at $158,000. Institutional investors and hedge funds own 24.41% of the company’s stock.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Stock Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related stocks with our FREE daily email newsletter.